Campath Antitrust Order Focuses On Off-Label Use In Organ Transplant Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering AG will take over sole rights for development and marketing of Campath as acute therapy for solid organ transplant rejection as a result of the Genzyme/Ilex merger